MVA-BN® HIV multiantigen
Therapeutic and prophylactic HIV vaccine candidate
The MVA-BN® HIV multiantigen vaccine encodes eight
genes from HIV, including Nef and thus represents a more advanced
vaccine candidate compared to Bavarian Nordic's previous MVA-based
HIV vaccine candidates, MVA HIV nef and MVA-BN® HIV
polytope. In previous clinical studies with MVA HIV
nef, Bavarian Nordic has demonstrated proof of concept for
the MVA technology's ability to control HIV replication.
Furthermore the vaccine was shown to be immunogenic and to induce a
broad T-cell response to Nef. The MVA-BN® HIV
multiantigen builds on these positive results and thus
represents an excellent opportunity to stimulate a broad immune
response to the majority of the HIV proteins that will likely have
important implications in a prophylactic and therapeutic setting
for HIV.
The first Phase I trial for this MVA-BN®-based prophylactic and
therapeutic HIV vaccine candidate vaccine completed enrolment in
2008. 15 HIV infected individuals (CD4 counts > 350 ul/ml) were
enrolled into this study. As previously reported the vaccine was
well tolerated and no serious adverse events were reported.
Preliminary immunogenicity data are just becoming available and
indicate that the HIV vaccine candidate was able to induce a broad
T-cell response (to multiple HIV proteins). A final study report is
expected in the second half of 2009.
